Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Insulin-sensitizing agent].

T Yamanouchi1

  • 1Department of Internal Medicine, University of Teikyo.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|April 13, 1999
PubMed
Summary
This summary is machine-generated.

Troglitazone, an insulin-sensitizing drug, effectively lowers blood sugar in some patients, especially the obese with hyperinsulinemia. However, it carries a risk of serious liver damage, requiring careful monitoring of liver enzymes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A mechanical coil insertion system for endovascular coil embolization of intracranial aneurysms.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2013
Same author

An algebraic description of painted digital pictures.

IEEE transactions on pattern analysis and machine intelligence·2012
Same author

Esophageal atresia with double tracheoesophageal fistula--a case report and review of the literature.

European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie·2005
Same author

Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2005
Same author

Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.

Diabetes, obesity & metabolism·2003
Same author

Effects of omega-3 fatty acids in rat allogenic small intestinal transplantation.

Pediatric surgery international·2003
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Hepatology

Background:

  • Troglitazone is an oral insulin-sensitizing agent belonging to the thiazolidinedione class.
  • Thiazolidinediones enhance insulin sensitivity in muscle, adipose tissue, and the liver.

Purpose of the Study:

  • To evaluate the therapeutic efficacy and safety profile of troglitazone.
  • To explore its potential in combination therapy for diabetes management.
  • To discuss the potential cardiovascular benefits and known risks of troglitazone.

Main Methods:

  • Clinical evaluation of troglitazone's effectiveness in improving glycemic control.
  • Assessment of troglitazone's efficacy in combination with other antidiabetic agents (sulfonylurea, metformin, insulin).
  • Monitoring of liver function tests (GOT, GPT, LDH) to detect potential hepatotoxicity.

Related Experiment Videos

Main Results:

  • Troglitazone shows effectiveness in improving glycemia, particularly in obese patients with hyperinsulinemia.
  • Some patients unresponsive to sulfonylureas show good response to troglitazone.
  • Combination therapy with troglitazone demonstrates therapeutic potential.
  • Serious liver damage has been recognized as a potential risk associated with troglitazone use.

Conclusions:

  • Troglitazone is a valuable therapeutic option for managing insulin resistance and improving glycemic control, especially in specific patient populations.
  • The potential for serious liver toxicity necessitates vigilant monitoring of liver function.
  • Further research is warranted to understand the mechanisms of troglitazone-induced liver injury and its long-term cardiovascular implications.